Treatment of Immune-Complex MPGN with Full-House Staining and Low Complement
This patient with immune-complex membranoproliferative glomerulonephritis (IC-MPGN) showing full-house staining, negative autoimmune and infection screens, but low C3 and C4 levels should be treated with mycophenolate mofetil (MMF) plus glucocorticoids as first-line therapy 1, 2.
Clinical Context and Diagnostic Interpretation
The full-house staining pattern (IgG, IgM, IgA, C3, C1q, kappa, lambda) with negative serologies creates a diagnostic challenge. This presentation suggests:
- Idiopathic immune complex glomerulonephritis (ICGN) - a diagnosis of exclusion after ruling out lupus, infection-related causes, and monoclonal gammopathies 3
- The low C3 and C4 indicate complement consumption, which can occur in both IC-MPGN and complement-mediated disease
- Full-house staining with negative ANA/anti-dsDNA does not exclude lupus nephritis entirely, but makes it less likely
Critical Caveat
Before finalizing the diagnosis of idiopathic IC-MPGN, ensure you have:
- Excluded occult malignancy (especially in patients >50 years)
- Performed serum/urine protein electrophoresis with immunofixation to rule out monoclonal gammopathy 3
- Considered repeat serologic testing, as lupus serology can occasionally be initially negative
- Evaluated for cryoglobulinemia if not already done
Treatment Algorithm
For Moderate-to-Severe Disease (eGFR ≥30 mL/min/1.73m²)
Initial therapy:
- MMF 1-2 g daily (divided doses) PLUS
- Glucocorticoids: Start with pulse methylprednisolone (typically 500-1000 mg IV for 3 days) followed by oral prednisone 1, 2
This recommendation is based on the 2021 KDIGO guideline's practice point for idiopathic ICGN, which represents the most current evidence-based approach 1, 2.
For Advanced Disease (eGFR <30 mL/min/1.73m²)
Supportive care alone is recommended 1 UNLESS:
- Active necrotizing or crescentic GN is present
- Significant acute tubular necrosis without extensive chronic changes
- Biopsy shows preserved renal parenchyma with minimal fibrosis/atrophy
The rationale: immunosuppression adds risk without benefit when chronic irreversible damage predominates.
If Initial Therapy Fails
Second-line options 1:
- Eculizumab (anti-C5 monoclonal antibody) - particularly if there is evidence of terminal complement activation (elevated sC5b-9 levels >1000 mg/mL) 4
- Clinical trial enrollment should be strongly considered, as effective therapies remain limited 1, 5
Monitoring Strategy
- Assess response at 3 months: Look for declining proteinuria and stable/improving renal function
- Consider repeat biopsy if worsening occurs during treatment to distinguish active inflammation from scarring 1
- Do not base treatment changes on complement levels alone - clinical and histologic parameters are more reliable
Important Nuances
The Complement Paradox
Low C3 and C4 with full-house staining creates diagnostic uncertainty. While this pattern suggests IC-MPGN, complement dysregulation can occur in both IC-MPGN and C3 glomerulopathy 5, 6. Recent evidence shows these represent a heterogeneous spectrum rather than distinct diseases 5. However, the presence of full immunoglobulin deposition (full-house) favors IC-MPGN over C3G.
Why Not Cyclophosphamide?
Unlike lupus nephritis where cyclophosphamide has strong evidence 7, 8, idiopathic IC-MPGN lacks robust data supporting cyclophosphamide use. The 2021 KDIGO guideline specifically recommends MMF plus steroids as the initial approach for idiopathic ICGN 1, 2.
The Eculizumab Question
While eculizumab has shown promise in select cases with evidence of terminal complement activation 4, its use should be reserved for refractory disease or patients with documented high sC5b-9 levels. The response is heterogeneous and may depend on the extent of terminal complement activation 5, 4.
Prognosis Considerations
The prognosis for idiopathic IC-MPGN remains poor despite immunosuppression 5. Factors suggesting worse outcomes include:
- Baseline renal dysfunction
- Extensive crescents or chronic changes on biopsy
- Persistent nephrotic-range proteinuria despite treatment
Duration of therapy: If remission is achieved, continue treatment for at least 12 months before considering tapering, similar to lupus nephritis maintenance strategies 8.